FDA Focus: What Mayer Brown's Practice Chair Is Watching
Christopher Mikson, newly christened leader of the U.S. Food and Drug Administration practice at Mayer Brown LLP, tells Law360 he's watching for a "dramatic increase" in biosimilar applications, a crackdown on...To view the full article, register now.
Already a subscriber? Click here to view full article